Announced Date: 2024-05-21 (May 21, 2024) Seller: ProfoundBio (China) Buyer: Genmab A/S (Denmark) Payment: USD 1.8 … [China Biotech M&A] Genmab Completes Acquisition of ProfoundBio for USD 1.8 billion in cash, obtain ADC Portfolio and PlatformRead more
[China BD 2024] Medshine and Erasca enters a License on selective KRAS inhibitor ERAS-4001
Announced Date: 2024-05-16 (May 16, 2024) Asset Name: ERAS-4001 Licensor (Seller): Medshine Discovery (China) Licensee (Buyer): … [China BD 2024] Medshine and Erasca enters a License on selective KRAS inhibitor ERAS-4001Read more
[China BD 2024] Joyo Pharma and Erasca enters a License on Pan-RAS molecular glue JYP0015 (ERAS-0015)
Announced Date: 2024-05-16 (May 16, 2024) Asset Name: JYP0015 (ERAS-0015) Licensor (Seller): Joyo Pharmatech (China) Licensee … [China BD 2024] Joyo Pharma and Erasca enters a License on Pan-RAS molecular glue JYP0015 (ERAS-0015)Read more
[China NewCo 2024] Hengrui and Hercules CM NewCo enters a license on 4 GLP-1 Programs
Announced Date: 2024-08-29 (May 29, 2024) Key Asset: Four GLP-1 Programs, HRS9531 (KAI-9531)、HRS-7535 (KAI-7535)、HRS-4729 (KAI-4729) Licensor: … [China NewCo 2024] Hengrui and Hercules CM NewCo enters a license on 4 GLP-1 ProgramsRead more
[China Original Asset] GSK and Aiolos Bio enters a 1.4 billion USD Acquisition for TSLP Abs AIO-001 (SHR-1905 from Hengrui)
Announced Date: 2024-01-09 (January 09, 2024) Buyer: GSK plc (GSK) Seller: Aiolos Bio, Inc. (Aiolos) Key … [China Original Asset] GSK and Aiolos Bio enters a 1.4 billion USD Acquisition for TSLP Abs AIO-001 (SHR-1905 from Hengrui)Read more
[China BD 2024] Allorion and Avenzo enters a 1 billion USD License on CDK2 Inhibitor AVZO-021 (ARTS-021)
Announced Date: 2024-01-04 (January 4, 2024) Asset Name: AVZO-021 (ARTS-021) Licensor (Seller): Allorion Therapeutics (China) Licensee … [China BD 2024] Allorion and Avenzo enters a 1 billion USD License on CDK2 Inhibitor AVZO-021 (ARTS-021)Read more
[China BD 2024] Argo and Novartis enters a 4 billion USD license on two RNAi programs
Announced Date: 2024-01-07 (January 7, 2024) Asset Name: Two RNAi programs (RNA interference) Licensor: Argo (Shanghai … [China BD 2024] Argo and Novartis enters a 4 billion USD license on two RNAi programsRead more
[China BD 2024] Insilico Medicine and Menarini (Stemline) enters a 512 million USD license on a preclinical KAT6 inhibitor ISM5043 (MEN2312)
Announced Date: 2024-01-04 (January 4, 2024) Asset Name: ISM5043 (MEN2312) Licensor: InSilico Medicine (China) Licensee (Buyer): … [China BD 2024] Insilico Medicine and Menarini (Stemline) enters a 512 million USD license on a preclinical KAT6 inhibitor ISM5043 (MEN2312) Read more
[China BD 2024] MediLink and Roche enters a 1 billion USD license on c-Met ADC YL211 (RG6648)
Announced Date: 2024-01-02 (January 2, 2024) Asset Name: YL211 (RG6648) Licensor: MediLink (MediLink Therapeutics, China) Licensee … [China BD 2024] MediLink and Roche enters a 1 billion USD license on c-Met ADC YL211 (RG6648)Read more
[China BD 2024] Allorion and AstraZeneca enters an Option and Global License on EGFR L858R Allosteric Inhibitor Asset
Announced Date: 2024-01-02 (January 2, 2024) Asset Name: Undisclosed Licensor (Seller): Allorion Therapeutics (China) Licensee (Buyer): AstraZeneca … [China BD 2024] Allorion and AstraZeneca enters an Option and Global License on EGFR L858R Allosteric Inhibitor AssetRead more